VOR Vor Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VOR

Price (delayed)

$1.8

Market cap

$122.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.75

Enterprise value

$124.59M

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that ...

Highlights
VOR's EPS is up by 25% YoY and by 7% from the previous quarter
The debt is down by 8% YoY and by 2.6% from the previous quarter
Vor Biopharma's quick ratio has decreased by 49% YoY and by 15% from the previous quarter
Vor Biopharma's equity has decreased by 40% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vorbiopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VOR
Market
Shares outstanding
68.17M
Market cap
$122.7M
Enterprise value
$124.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$117.86M
EBITDA
-$109.64M
Free cash flow
-$101.36M
Per share
EPS
-$1.75
Free cash flow per share
-$1.51
Book value per share
$2.22
Revenue per share
$0
TBVPS
$2.95
Balance sheet
Total assets
$198.13M
Total liabilities
$47.4M
Debt
$35.66M
Equity
$150.72M
Working capital
$125.23M
Liquidity
Debt to equity
0.24
Current ratio
9.04
Quick ratio
8.96
Net debt/EBITDA
-0.02
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.6%
Return on equity
-62%
Return on invested capital
-53.5%
Return on capital employed
-64.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VOR stock price

How has the Vor Biopharma stock price performed over time
Intraday
2.27%
1 week
6.51%
1 month
-14.29%
1 year
-54.31%
YTD
-20%
QTD
-24.05%

Financial performance

How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.04M
Net income
-$117.86M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 35% YoY and by 2.8% QoQ
The net income has contracted by 28% YoY and by 2% from the previous quarter

Growth

What is Vor Biopharma's growth rate over time

Valuation

What is Vor Biopharma stock price valuation
P/E
N/A
P/B
0.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS is up by 25% YoY and by 7% from the previous quarter
Vor Biopharma's equity has decreased by 40% YoY and by 14% from the previous quarter
VOR's price to book (P/B) is 26% less than its last 4 quarters average of 1.1

Efficiency

How efficient is Vor Biopharma business performance
The company's return on equity fell by 31% YoY and by 15% QoQ
The return on assets has declined by 30% year-on-year and by 13% since the previous quarter
The return on invested capital has declined by 13% year-on-year and by 11% since the previous quarter

Dividends

What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VOR.

Financial health

How did Vor Biopharma financials performed over time
Vor Biopharma's current ratio has decreased by 50% YoY and by 15% from the previous quarter
Vor Biopharma's quick ratio has decreased by 49% YoY and by 15% from the previous quarter
The debt is 76% less than the equity
Vor Biopharma's debt to equity has surged by 50% YoY and by 14% QoQ
Vor Biopharma's equity has decreased by 40% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.